468 related articles for article (PubMed ID: 29078283)
1. Humanized mouse model supports development, function, and tissue residency of human natural killer cells.
Herndler-Brandstetter D; Shan L; Yao Y; Stecher C; Plajer V; Lietzenmayer M; Strowig T; de Zoete MR; Palm NW; Chen J; Blish CA; Frleta D; Gurer C; Macdonald LE; Murphy AJ; Yancopoulos GD; Montgomery RR; Flavell RA
Proc Natl Acad Sci U S A; 2017 Nov; 114(45):E9626-E9634. PubMed ID: 29078283
[TBL] [Abstract][Full Text] [Related]
2. Enhanced development of functional human NK cells in NOD-scid-IL2rg
Aryee KE; Burzenski LM; Yao LC; Keck JG; Greiner DL; Shultz LD; Brehm MA
FASEB J; 2022 Sep; 36(9):e22476. PubMed ID: 35959876
[TBL] [Abstract][Full Text] [Related]
3. Development of Humanized Mouse Models for Studying Human NK Cells in Health and Disease.
Shan L; Flavell RA; Herndler-Brandstetter D
Methods Mol Biol; 2022; 2463():53-66. PubMed ID: 35344167
[TBL] [Abstract][Full Text] [Related]
4. Long-term human CD34+ stem cell-engrafted nonobese diabetic/SCID/IL-2R gamma(null) mice show impaired CD8+ T cell maintenance and a functional arrest of immature NK cells.
André MC; Erbacher A; Gille C; Schmauke V; Goecke B; Hohberger A; Mang P; Wilhelm A; Mueller I; Herr W; Lang P; Handgretinger R; Hartwig UF
J Immunol; 2010 Sep; 185(5):2710-20. PubMed ID: 20668220
[TBL] [Abstract][Full Text] [Related]
5. Targeted genome editing restores T cell differentiation in a humanized X-SCID pluripotent stem cell disease model.
Alzubi J; Pallant C; Mussolino C; Howe SJ; Thrasher AJ; Cathomen T
Sci Rep; 2017 Sep; 7(1):12475. PubMed ID: 28963568
[TBL] [Abstract][Full Text] [Related]
6. hIL-15-gene modified human natural killer cells (NKL-IL15) exhibit anti-human leukemia functions.
Jiang W; Zhang C; Tian Z; Zhang J
J Cancer Res Clin Oncol; 2018 Jul; 144(7):1279-1288. PubMed ID: 29737430
[TBL] [Abstract][Full Text] [Related]
7. Humanized Mouse Models for the Advancement of Innate Lymphoid Cell-Based Cancer Immunotherapies.
Horowitz NB; Mohammad I; Moreno-Nieves UY; Koliesnik I; Tran Q; Sunwoo JB
Front Immunol; 2021; 12():648580. PubMed ID: 33968039
[TBL] [Abstract][Full Text] [Related]
8. In Vivo Activation of Human NK Cells by Treatment with an Interleukin-15 Superagonist Potently Inhibits Acute In Vivo HIV-1 Infection in Humanized Mice.
Seay K; Church C; Zheng JH; Deneroff K; Ochsenbauer C; Kappes JC; Liu B; Jeng EK; Wong HC; Goldstein H
J Virol; 2015 Jun; 89(12):6264-74. PubMed ID: 25833053
[TBL] [Abstract][Full Text] [Related]
9. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
Jiang W; Zhang C; Tian Z; Zhang J
Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
[TBL] [Abstract][Full Text] [Related]
10. A functional DC cross talk promotes human ILC homeostasis in humanized mice.
Lopez-Lastra S; Masse-Ranson G; Fiquet O; Darche S; Serafini N; Li Y; Dusséaux M; Strick-Marchand H; Di Santo JP
Blood Adv; 2017 Apr; 1(10):601-614. PubMed ID: 29296702
[TBL] [Abstract][Full Text] [Related]
11. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
[TBL] [Abstract][Full Text] [Related]
12. The combination of NK and CD8+T cells with CCL20/IL15-armed oncolytic adenoviruses enhances the growth suppression of TERT-positive tumor cells.
Ye JF; Qi WX; Liu MY; Li Y
Cell Immunol; 2017 Aug; 318():35-41. PubMed ID: 28651743
[TBL] [Abstract][Full Text] [Related]
13. Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy.
Ayello J; Hochberg J; Flower A; Chu Y; Baxi LV; Quish W; van de Ven C; Cairo MS
Exp Hematol; 2017 Feb; 46():38-47. PubMed ID: 27765614
[TBL] [Abstract][Full Text] [Related]
14. IL-15 has innate anti-tumor activity independent of NK and CD8 T cells.
Davies E; Reid S; Medina MF; Lichty B; Ashkar AA
J Leukoc Biol; 2010 Sep; 88(3):529-36. PubMed ID: 20538758
[TBL] [Abstract][Full Text] [Related]
15. Adoptive transfer of osteoclast-expanded natural killer cells for immunotherapy targeting cancer stem-like cells in humanized mice.
Kozlowska AK; Kaur K; Topchyan P; Jewett A
Cancer Immunol Immunother; 2016 Jul; 65(7):835-45. PubMed ID: 27034236
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells.
Andrews KJ; Ribas A; Butterfield LH; Vollmer CM; Eilber FC; Dissette VB; Nelson SD; Shintaku P; Mekhoubad S; Nakayama T; Taniguchi M; Glaspy JA; McBride WH; Economou JS
Cancer Res; 2000 Nov; 60(22):6457-64. PubMed ID: 11103813
[TBL] [Abstract][Full Text] [Related]
17. Innate Response to Human Cancer Cells with or without IL-2 Receptor Common γ-Chain Function in NOD Background Mice Lacking Adaptive Immunity.
Nishime C; Kawai K; Yamamoto T; Katano I; Monnai M; Goda N; Mizushima T; Suemizu H; Nakamura M; Murata M; Suematsu M; Wakui M
J Immunol; 2015 Aug; 195(4):1883-90. PubMed ID: 26170385
[TBL] [Abstract][Full Text] [Related]
18. Distinct cell types control lymphoid subset development by means of IL-15 and IL-15 receptor alpha expression.
Schluns KS; Nowak EC; Cabrera-Hernandez A; Puddington L; Lefrançois L; Aguila HL
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5616-21. PubMed ID: 15060278
[TBL] [Abstract][Full Text] [Related]
19. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation.
Wu Z; Xu Y
J Mol Cell Biol; 2010 Aug; 2(4):217-22. PubMed ID: 20671116
[TBL] [Abstract][Full Text] [Related]
20. Antitumor immune response of human peripheral blood lymphocytes coengrafted with tumor into severe combined immunodeficient mice.
Iwanuma Y; Chen FA; Egilmez NK; Takita H; Bankert RB
Cancer Res; 1997 Jul; 57(14):2937-42. PubMed ID: 9230205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
